March 202430
Oral minoxidil for pattern hair loss won 81% support among surveyed US dermatology providers, with 89% reporting patients tolerate it well. Topical betamethasone versus minoxidil proved more effective for alopecia areata, achieving 74% versus 42% response. Occluded topical corticosteroids in children produced significant regrowth in 83% with severe alopecia areata, though four developed suspected adrenal insufficiency before recovering. Penguin Cold Caps during chemotherapy helped 92% keep at least half their hair, with doxorubicin regimens working least well. Minoxidil-loaded nanoliposomes in mice grew more hair and reduced scalp bacteria more than free minoxidil.
- Survey of Dermatology Practitioners' Opinions and Prescribing Habits of Oral Minoxidil for the Treatment of Androgenetic Alopecia. A survey of US dermatology providers found 81% support oral minoxidil for pattern hair loss, and 89% report it is well tolerated by patients.
- Efficacy and Safety of Topical Corticosteroid Treatment under Occlusion for Severe Alopecia Areata in Children. A single-center retrospective analysis In a retrospective study, 83% of children with severe alopecia areata achieved significant regrowth with occluded topical corticosteroids; four had suspected adrenal insufficiency but recovered.
- Cytoprotective role of human dental pulp stem cell-conditioned medium in chemotherapy-induced alopecia In mice, hypoxic-conditioned dental pulp stem cell medium accelerated hair regrowth after chemotherapy without promoting tumor growth.
- Comparison of Efficacy of Topical Betamethasone Dipropionate and Topical Minoxidil in Patients With Alopecia Areata In a nonrandomized study of 100 patients, topical betamethasone was significantly more effective than minoxidil for alopecia areata (74% vs 42% response).
- Retrospective evaluation of Penguin Cold Caps for chemotherapy-induced alopecia In a 100-patient retrospective cohort, 92% kept at least half their hair with manual cold caps; doxorubicin regimens worked least well.
- DNA methylation of microRNA-365-1 induces apoptosis of hair follicle stem cells by targeting DAP3 In mice with cyclophosphamide-induced hair loss, miR-365-1 methylation triggered hair-follicle stem cell death via DAP3.
- Examining the Uncertainties Surrounding Exosome Therapy in Androgenetic Alopecia: A Call for Evidence-Based Practice. A review examines the current state of exosome therapy for pattern hair loss, noting limitations and directions for future research.
- Minoxidil nanoliposomes as a hair growth stimulator and a scalp disinfectant. In mice, minoxidil-loaded nanoliposomes grew more hair and reduced scalp bacteria more than free minoxidil.
- Estimation of health utility values for alopecia areata UK public interviews rated severe alopecia areata utility at 0.502 versus 0.919 for minimal hair loss.
- The Effects of Negative Pressure Therapy on Hair Growth of Mouse Models In nude mice, negative pressure therapy increased hair follicle density and angiogenesis, with 15-minute sessions showing the highest follicle density.
- Extracellular Caspase-1 induces hair stem cell migration in wounded and inflamed skin conditions Extracellular Caspase-1 secreted after wounding triggers hair follicle stem cells to migrate into the epidermis.
- Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries A European survey found alopecia areata patients with atopic, autoimmune, or psychiatric comorbidities had more severe disease and received more systemic treatments.
- The impact of appendectomy on the occurrence of alopecia areata: a retrospective cohort study In a 16,385-person retrospective cohort, appendectomy was linked to a 2.27-fold higher risk of alopecia areata.
- Attenuation of disease process following treatment with low-dose naltrexone in patients with frontal fibrosing alopecia and lichen planopilaris: A retrospective study low-dose naltrexone attenuated disease progression in frontal fibrosing alopecia and lichen planopilaris in a retrospective study.
- Vibration assisted analgesia during intralesional corticosteroid therapy for alopecia Vibration-assisted analgesia safely reduced pain during intralesional corticosteroid injections for inflammatory hair loss.
- Dandruff lesional scalp skin exhibits epidermal T cell infiltration and a weakened hair follicle immune privilege Dandruff-affected scalp shows T-cell infiltration and weakened hair follicle immune privilege in human biopsies.
- Exploring the Gut Microbiome and Metabolome in Individuals with Alopecia Areata Disease An observational study found reduced gut microbial diversity and candidate microbial and metabolite biomarkers in alopecia areata patients.
- Optimization of Bear Oil Extraction Process and Hair Growth Activity In mice, bear grease applied to shaved skin increased hair length, weight and follicle numbers.
- Alopecia areata treatment with baricitinib: different relapse phenotypes alopecia areata patients treated with baricitinib show different relapse phenotypes.
- SPRY1 Deficiency in Keratinocytes Induces Follicular Melanocyte Stem Cell Migration to the Epidermis through p53/Stem Cell Factor/C-KIT Signaling In mice, keratinocyte SPRY1 loss drove hair-follicle melanocyte stem cells to migrate into the epidermis via p53/SCF/C-KIT signaling.
- A review of isotretinoin in the treatment of frontal fibrosing alopecia A review of 232 patients found nearly 90% experienced reduced symptoms with isotretinoin for frontal fibrosing alopecia.
- Safety and Efficacy of Minoxidil Treatment in Scarring Alopecia: A Scoping Review. A scoping review found minoxidil shows promise for scarring alopecia but with mixed results and some side effects, requiring further research.
- Alopecia Areata: Review of Epidemiology, Pathophysiology, Current Treatments and Nanoparticulate Delivery System A review covers alopecia areata causes, current treatments, and nanoparticle drug-delivery approaches.
- MiR‐200c‐3p as a novel genetic marker and therapeutic tool for alopecia areata miR-200c-3p levels were higher in 65 alopecia areata patients than in matched healthy controls, suggesting a possible marker role.
- Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series Five treatment-resistant alopecia areata patients achieved satisfactory regrowth on upadacitinib 15 mg daily without adverse events.
- Efficacy and Safety of Skin Radiance Collagen on Skin and Hair Matrix: A Placebo-Controlled Clinical Trial in Healthy Human Subjects In a trial of healthy women, a collagen supplement reduced hair fall by 28% and improved skin hydration after 56 days.
- Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey An 11-country survey of 747 people with severe alopecia areata found major quality-of-life and mental health impacts.
- Compatibility of Caffeine Clobetasol Propionate Dutasteride Nicotinamide and Progesterone in TrichoFoam™, a Natural Vehicle for Hair Foams. Lab tests show caffeine, dutasteride and other actives remain stable in TrichoFoam vehicle for 90-180 days, except clobetasol (14 days) and high-dose dutasteride (30 days).
- Tangled Truths: Unraveling the Link Between Frontal Fibrosing Alopecia and Allergic Contact Dermatitis A review explores the potential link between allergic contact dermatitis and frontal fibrosing alopecia.
- Spanlastic-laden nanogel as a plausible platform for dermal delivery of bimatoprost with superior cutaneous deposition and hair regrowth efficiency in androgenic alopecia